Univariate PFS | Univariate OS | |||
HR (95% CI) | P value | HR (95% CI) | P value | |
uPAR+ EVs from melanoma | ||||
First quartile | Ref | Ref | ||
Second quartile | 2.166 (0.8816 to 5.319) | 0.091963 | 15.69 (2.037 to 120.8) | 0.008214 |
Third quartile | 4.758 (2.0121 to 11.253) | 0.000382 | 24.81 (3.259 to 188.9) | 0.001930 |
Fourth quartile | 6.695 (2.8076 to 15.966) | 1.8e-0.5 | 34.99 (4.572 to 267.8) | 0.000618 |
uPAR+ EVs from B cells | ||||
First quartile | Ref | Ref | ||
Second quartile | 2.428 (1.1151 to 5.287) | 0.0255 | 3.276 (1.2528 to 8.566) | 0.0155 |
Third quartile | 1.959 (0.8736 to 4.393) | 0.1027 | 2.801 (1.0322 to 7.600) | 0.0432 |
Fourth quartile | 1.690 (0.7560 to 3.778) | 0.2011 | 2.5360 (0.9342 to 6.884) | 0.0678 |
uPAR+EVs from CD8+T cells | ||||
First quartile | Ref | Ref | ||
Second quartile | 1.759 (0.7364 to 4.201) | 0.203706 | 6.945 (1.537 to 31.38) | 0.11767 |
Third quartile | 3.071 (1.3359 to 7.061) | 0.008245 | 11.451 (2.596 to 50.51) | 0.001281 |
Fourth quartile | 5.014 (2.1778 to 11.543) | 0.000151 | 13.803 (3.125 to 60.97) | 0.000534 |
uPAR+EVs from DC | ||||
First quartile | Ref | Ref | ||
Second quartile | 1.258 (0.5514 to 2.869) | 0.58578 | 1.981 (0.6763 to 5.806) | 0.2125 |
Third quartile | 1.725 (0.7695 to 3.868) | 0.18554 | 3.331 (1.1819 to 9.385) | 0.0228 |
Fourth quartile | 3.285 (1.5054 to 7.167) | 0.00281 | 3.642 (1.3060 to 10.154) | 0.0135 |
BRAF | ||||
wt | Ref | Ref | ||
Mutated | 1.179 (0.6765 to 2.056) | 0.561 | 1.454 (0.7738 to 2.732) | 0.245 |
No of metastatic sites | ||||
1–2 | Ref | Ref | ||
≥3 | 1.547 (0.9001 to 2.66) | 0.114 | 2.001 (1.087 to 3.685) | 0.0259 |
LDH | ||||
<ULN | Ref | Ref | ||
>ULN | 0.8219 (0.476 to 1.419) | 0.482 | 0.9127 (0.4941 to 1.686) | 0.771 |
Previous therapy for metastatic disease | ||||
No | Ref | Ref | ||
Yes | 1.017 (0.5909 to 1.75) | 0.952 | 1.499 (0.8137 to 2.762) | 0.194 |
DC, dendritic cell; EVs, extracellular vesicles; HR, higher quartiles; LDH, lactate dehydrogenase; OS, overall survival; PFS, progression-free survival; ULN, upper limit of normal; uPAR, urokinase-type plasminogen activator receptor.